Harrow (NASDAQ:HROW) CFO Buys $104,650.00 in Stock

Harrow, Inc. (NASDAQ:HROW) CFO Andrew Boll bought 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was bought at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the acquisition, the chief financial officer directly owned 814,679 shares in the company, valued at approximately $24,358,902.10. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $31.21 on Monday. Harrow, Inc. has a 52-week low of $25.21 and a 52-week high of $54.85. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -76.12 and a beta of 0.34. The stock’s fifty day simple moving average is $36.51 and its 200 day simple moving average is $42.16.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The business had revenue of $44.20 million for the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter in the prior year, the firm posted ($0.38) EPS. As a group, sell-side analysts forecast that Harrow, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HROW has been the topic of a number of research analyst reports. B. Riley Financial reiterated a “buy” rating and set a $65.00 price target (down from $74.00) on shares of Harrow in a report on Tuesday, April 7th. Wall Street Zen downgraded Harrow from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Harrow in a report on Thursday, March 19th. Finally, William Blair reiterated an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $69.43.

Institutional Trading of Harrow

A number of institutional investors have recently bought and sold shares of HROW. University of Texas Texas AM Investment Management Co. acquired a new stake in Harrow during the fourth quarter valued at $26,000. KBC Group NV acquired a new stake in Harrow during the first quarter valued at $31,000. Raymond James Financial Inc. acquired a new stake in Harrow during the second quarter valued at $48,000. SBI Securities Co. Ltd. boosted its position in Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after purchasing an additional 846 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in Harrow during the third quarter valued at $83,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.